



## **CLL Live Conference: Many Reasons for Hope**

CLL Live 2018 registration is currently full and we have started a wait list. At past conferences, a number of people were unable to attend and places opened up for those on the wait list. To register for the wait list and for more information, visit [cllpag.ca](http://cllpag.ca)

---

## **pCODR Recommends Reimbursement of Venetoclax**

In a surprise [decision](#), pCODR, the federal agency that recommends whether a drug should be on provincial formularies, has reversed its initial decision and recommended that Venetoclax be reimbursed. This is the first time that pCODR has reversed an initial decision. See the joint CLLPAG/ Lymphoma Canada response to the initial [decision](#).

---

## **IgHV and TP53 Testing in Ontario**

To determine if untreated patients are eligible for Ibrutinib, Ontario will fund testing of two CLL prognostic markers: IgHV mutation status and the presence of the TP53 mutation. Implementation of these very positive steps are being worked out and we will report new information as it is received.

---

## **Making Empowered Decisions: Patient Power Webinar**

Don't miss this Patient Power webinar from MD Anderson Cancer Center on Saturday, March 24 at 11:30 EST. Learn about your options for best CLL care, the latest therapies and how to identify the best treatment for you. For more information, visit [patientpower.info/march24](http://patientpower.info/march24)

---

## **CLL Resource List**

Check out [cllpag.ca](http://cllpag.ca) for the revised CLL Resource List. Thanks to those of you who submitted additional items for inclusion on the list.

---